What is the clinical significance of a peri‑appendiceal red patch (caecal patch) in ulcerative colitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Significance of Peri-Appendiceal Red Patch (Caecal Patch) in Ulcerative Colitis

When you identify a peri-appendiceal red patch (PARP) or caecal patch in a patient with newly diagnosed ulcerative colitis, you must perform small bowel imaging in addition to ileocolonoscopy to exclude Crohn's disease, as this atypical finding raises diagnostic uncertainty. 1

Diagnostic Implications

Immediate Workup Required

  • Small bowel evaluation is mandatory when PARP is present at initial diagnosis, using CT enterography, MR enterography, or other appropriate imaging modalities 1, 2
  • The presence of PARP in left-sided colitis represents a skip lesion pattern that deviates from the typical continuous inflammation of UC 1
  • PARP occurs in approximately 7.9% to 17.7% of UC patients without pancolitis 3, 4

Diagnostic Accuracy

  • PARP has 95.2% specificity but only 28.3% sensitivity for UC diagnosis when diffuse distal colorectal inflammation is present 5
  • In patients with distal inflammatory changes plus PARP, the positive UC diagnosis rate reaches 96.5% versus 78.0% without PARP 5
  • However, 9.8% of patients initially diagnosed with left-sided UC and PARP are eventually rediagnosed with Crohn's disease, compared to only 1.0% without PARP 6

Prognostic Significance

Disease Progression Risk

Patients with PARP demonstrate significantly higher rates of proximal disease extension and require more aggressive medical management: 3, 6

  • 35.6% develop proximal extension of inflammation versus 10.0% in left-sided UC without PARP 6
  • 81.8% require upscaling of medical therapy compared to 58.0% without PARP 3
  • 13.6% undergo colectomy versus 4.9% in patients without PARP 3

Patient Demographics

PARP predominantly occurs in: 3, 6, 4

  • Younger patients (median age 31 years versus 41 years) 6
  • Those with shorter disease duration 3
  • Male patients (79% in one series) 4
  • Patients with rectosigmoid-limited disease (58.8% versus 28.4%) 6

Histopathological Correlation

Appendiceal Inflammation

PARP strongly predicts active histological appendiceal inflammation: 7, 3

  • Patients with PARP have significantly higher Robarts Histopathology Index scores (median RHI 14-15.5 versus 5.0-7.0 without PARP) 7, 3
  • Active appendiceal inflammation is present in 55.4% of UC patients in remission 7
  • Histological activity in PARP parallels the activity of distal colitis in 67% of cases 4

Clinical Relevance for Appendectomy

  • Extensive epithelial neutrophil involvement (>5% of crypts) in the appendix associates with 44.4% relapse rates versus 18.0% 7
  • PARP presence on colonoscopy can identify patients with appendiceal inflammation who may benefit from appendectomy as experimental therapy 3
  • Active appendiceal inflammation shows a trend toward association with relapse risk in quiescent UC 7

Long-Term Outcomes

Disease Behavior

Despite increased treatment escalation needs, PARP does not affect certain long-term outcomes: 1, 6, 5

  • No increased risk of colorectal neoplasia 6
  • No difference in treatment efficacy when comparing modified Mayo scores or Baron grading 5
  • Natural history appears similar to isolated left-sided UC regarding remission, relapse, and mortality rates 1

Common Pitfalls to Avoid

  • Do not assume PARP represents typical UC progression - always exclude Crohn's disease with small bowel imaging 1, 2
  • Do not dismiss PARP as clinically insignificant - these patients require closer monitoring for disease extension 3, 6
  • Do not confuse PARP with appendiceal skip lesions - the latter occurs in up to 75% of UC patients and has different prognostic implications 1, 2
  • PARP can be present even during endoscopic remission (61.4% of cases), so assess for it regardless of disease activity 3

Practical Management Algorithm

  1. At diagnosis: Document PARP presence during initial colonoscopy 2
  2. If PARP present: Order small bowel imaging (CT/MR enterography) to exclude Crohn's disease 1
  3. Obtain biopsies: From both PARP area and distal inflammation to assess parallel activity 4
  4. Plan closer surveillance: Anticipate need for treatment escalation and monitor for proximal extension 3, 6
  5. Consider appendiceal assessment: If appendectomy is being considered as experimental therapy, PARP predicts appendiceal inflammation 3

References

Related Questions

How do I differentiate colitis from gastroenteritis and what are the recommended treatments for each condition?
What is the colitis index and how is it calculated to assess ulcerative colitis severity?
When can chemotherapy be safely resumed after colitis resolves, and what dosing or regimen modifications are recommended?
What is the recommended diagnostic workup and management for colitis?
Can infectious colitis cause rectal bleeding?
What is the optimal treatment for herpes labialis occurring on a lip tattoo?
What are the Indian Council of Medical Research (ICMR) guidelines for re‑introducing antitubercular drugs in patients with liver disease?
What is the medical term for bruising of the eyes and forehead?
Can amiodarone aggravate a junctional rhythm?
What is the appropriate dosing regimen of trimethoprim‑sulfamethoxazole (Bactrim) for an adult with acute kidney injury and an estimated creatinine clearance of approximately 30 mL/min?
What are the recommended dose escalation strategies for biologic agents (e.g., anti‑TNF, vedolizumab, ustekinumab) and Janus kinase (JAK) inhibitors (e.g., tofacitinib, upadacitinib, filgotinib, baricitinib) in inflammatory bowel disease patients with inadequate response after standard induction?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.